Hospitalization and medication use in schizophrenia patients receiving risperidone long-acting injectable or oral atypical antipsychotic medication

被引：3
|
作者：
Chue, P
Lam, A
Chandra, K
Luong, D
Camacho, F
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Janssen Ortho Inc, Toronto, ON, Canada
[3] McKesson Phase 4 Solut, Toronto, ON, Canada
[4] Damos Inc, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67768-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A202 / A202
页数：1
相关论文
共 50 条
  • [31] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Kim, H.
    Hong, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S456
  • [32] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Ciwoniuk, M.
    Godlewska, B. R.
    Olajossy-Hilkesberger, L.
    Olajossy, M.
    Marmurowska-Michalowska, H.
    Limon, J.
    Landowski, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S457
  • [33] Efficacy and safety of long-acting injectable risperidone in patients with schizophrenia
    Bouhours, P
    Schreiner, A
    Rendall, MR
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 170 - 171
  • [34] Use of Long-Acting Injectable Paliperidone to Increase Medication Compliance in Individuals with ESRD and Schizophrenia
    Ruppert, Ryan
    Bryant, Cody
    Lifland, Brooke
    Cho, Stephanie
    JOURNAL OF THE ACADEMY OF CONSULTATION-LIAISON PSYCHIATRY, 2023, 64 : S100 - S101
  • [35] The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable
    Gharabawi, Georges
    Bossie, Cynthia
    Turkoz, Ibrahim
    Kujawa, Mary
    Mahmoud, Ramy
    Simpson, George
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2007, 195 (12) : 976 - 982
  • [36] Long-acting, injectable risperidone a direct transition from oral atypical antipsychotics
    Schmauss, M
    Schreiner, A
    EUROPEAN PSYCHIATRY, 2005, 20 : S76 - S76
  • [37] Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable
    Llorca, Pierre-Michel
    Kahn, Jean-Pierre
    Moreau-Mallet, Veronique
    Bouhours, Philippe
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2006, 10 (04) : 276 - 284
  • [38] Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with 291 schizophrenia
    De Marinis, T.
    Saleem, P. T.
    Glue, P.
    Arnoldussen, W. J.
    Teijeirol, R.
    Lex, A.
    Latif, M. A.
    Medori, R.
    PHARMACOPSYCHIATRY, 2007, 40 (06) : 257 - 263
  • [39] Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia
    Kim, Sung-Wan
    Kim, Ki-Min
    Kim, Jae-Min
    Shin, Il-Seon
    Shin, Hee-Young
    Yang, Su-Jin
    Yoon, Jin-Sang
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (02): : 543 - 545
  • [40] Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study
    Fortea, Adriana
    Ilzarbe, Daniel
    Espinosa, Laura
    Solerdelcoll, Mireia
    de Castro, Clara
    Oriolo, Giovanni
    Sugranyes, Gisela
    Baeza, Inmaculada
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (04) : 252 - 257
12345